Varex Imaging Corporation (VREX)
Healthcare
- Fundamental
- 3
- Sentiment
- 4
- Technical
- 2
Do Nothing: ATR14 0.07 is 0.38% of price, below the 1.0% minimum-ATR floor - VREX is merger-pinned at $18.41 against Teledyne's fixed $18.90 cash consideration, and neither a breakout stop above the 18.45-18.49 range top nor a pullback limit near the 18.40 floor can produce an ATR-scaled target the floor admits.
Company overview
Varex Imaging Corporation develops and manufactures X-ray imaging components. It operates in two segments: Medical, offering X-ray tubes, digital detectors, and software solutions for diagnostics and therapy; and Industrial, providing X-ray technology for security and inspection applications. The company serves a global market through direct sales and partnerships.
Fundamental
fairVarex Imaging shows slow growth and thin margins, with significant cash flow normalization needed due to non-recurring items.
Mixed: a slow-growth, thin-margin X-ray component supplier with weak trailing free cash flow and about 2.9x net leverage, whose GAAP results are distorted in both directions (a $93.9M goodwill impairment a year ago, a roughly $10M tariff-refund benefit in the latest quarter) - but with comfortable liquidity, no distress markers, and a signed all-cash Teledyne takeover at $18.90 per share that caps the equity outcome pending multi-jurisdiction clearance.
Sentiment
goodSentiment is stable, supported by positive media coverage and no significant retail or legal issues.
The dominant driver is the pending all-cash Teledyne acquisition at $18.90 per share (announced; special stockholder meeting 2026-10-28, with the timetable backed by the DEFM14A and 8-K), which leaves the stock at $18.41 with a live cash spread. Media polarity is positive in both measured windows (+0.70 baseline to +0.40 scoring - a composition-driven cooling rather than a deterioration, with no negative-scored coverage), retail chatter is absent, and the Red-Flag Screen is clean, so no severe or moderate cap applies.
Technical
weakThe stock is pinned to a fixed cash bid, with no swing setup due to compressed price movement.
Valid but non-tradeable chart: VREX is merger-pinned at $18.41 against Teledyne's fixed $18.90 all-cash consideration. All short-term averages are compressed into an 18.40-18.47 band (price below SMA20 18.45 and SMA50 18.47, marginally above EMA21 18.40), MACD line is above zero (+0.10) but below its signal with a -0.06 histogram that has been negative for a month, RSI14 holds 60.3 on a flat tape, and ADX14 40.9 is a residual of the August re-rating rather than a live trend. ATR14 is 0.07, only 0.38% of price, so the stock cannot reach an ATR-scaled target; the 1-15 day return here is deal-spread capture, not a directional swing, and the minimum-ATR floor suppresses the entry.
You’re looking at 2026-10-22 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

